ArticleACR open rheumatology2025
Characterization of Second-Line Therapy After First JAK Inhibitor Use: Results From the CorEvitas Rheumatoid Arthritis Registry.
Joshua F Baker et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this paperpooled itcites it